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Hemophagocytosis represents the peculiar 
pathological feature of activated macrophages 
engulfing hematopoietic cells as a result of an 
immune dysregulatory disorder. This find-
ing is the hallmark of a rare hyperinflam-
matory disease known as hemo phagocytic 
ly mphohistiocytosis (HLH).
HLH is a severe condition characterized 
by an abnormal ineffective immune response 
caused by an uncontrolled activation and 
proliferation of macrophages, natural killer 
(NK) cells and T-helper lymphocytes, leading 
to excessive cytokine production, subsequent 
amplification of pathologic immune stimula-
tion, increased phagocytic activity and tissue 
damage [1]. Typically, heat shock proteins 
(HSP) are associated with a peculiar combi-
nation of clinical and biochemical features, 
including prolonged high fever, pancytope-
nia, hepatosplenomegaly, hypertriglyceride-
mia, hyperferritinemia and hemophagocy-
tosis in the bone marrow. If undiagnosed or 
not promptly treated, HLH almost inevitably 
results in death.
First described in 1939 by Scott and 
Robb-Smith [2] as a life-threatening disor-
der characterized by histiocytic proliferation 
with erytrophagocytosis in the lymphore-
ticular system, it was named ‘histiocytic 
medullary reticulosis’ (HMR) and ascribed 
among malignant histiocytosis. In the fol-
lowing years, HSP were considered a heredi-
tary immune dysregulatory disorder, called 
‘familial hemophagocytic reticulosis’ [3], 
until Risdall described a viral association 
with HLH, highlighting a possible acquired 
etiology and therefore referring to it as ‘reac-
tive hemophagocytic syndrome’ [4]. Sub-
sequently, several cases have been involved 
in the genesis of sporadic HLH, including 
infections, malignancies, autoimmune dis-
eases and metabolic co nditions.
Therefore, HLH can be etiologically clas-
sified into a primary (genetic) or a secondary 
(acquired) disorder. All forms of HLH share 
hereditary or acquired immune defects char-
acterized by impaired function of NK cells 
and cytotoxic T cells.
Primary HLH includes two groups: first, 
the familial hemophagocytic lymphohistio-
cytosis syndromes (FHLH1–5), in which 
HLH is the sole manifestation of the dis-
ease, and second, immunodeficiency syn-
dromes associated with albinism (Chédiak 
Higashi syndrome, Griscelli syndrome 
type II, Hermansky-Pudlak syndrome type 
II) or other primary immunodeficiencies 
(i.e., X-linked lymphoproliferative disorder 
type I or II), where the hemophagocytosis 
is a part of a complex landscape of clinical 
manifestations [5]. Although not yet entirely 
identified, the known genetic abnormali-
ties cause defect in proteins (like perforin, 
MUNC13.4, syntaxin-11 and STXBP2) 
that play a key role in granule-dependent 
lymphocyte cytotoxicity, impairing the mat-
uration or the secretion cytotoxic granules 
during target cell killing, thus prejudicing 
the immune response [6]. Hereditary HLH 
usually occurs in infants or young children, 
with clear familial inheritance, is associ-
ated with high risk of recurrence and short 
life expectancy without hematopoietic cell 
transplantation.
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Secondary HLH, currently more common than pri-
mary forms, affects older children or adults without 
known genetic cause. Several pathological conditions 
may act as a trigger for the development of acquired 
HLH.
Infections, mainly viral and Epstein–Barr virus 
(EBV) associated, but also caused by bacterial, fungal 
and parasitic organisms, play a crucial role. However, 
infections may also represent the stimulus responsible 
for an acute exacerbation of primary forms of HLH; 
moreover, there is often an overlap between HLH 
secondary to infection and a septic process, whose 
di fferential diagnosis is extremely complex [7].
HLH is associated with several disorders of the 
immune system, including autoimmune disorders, 
being lupus erythematosus the most frequently 
reported one, acquired immune deficiencies (such as 
AIDS) or immune disorders after hematopoietic stem 
cell transplantation. Macrophage activation syndrome 
can be considered as a variant of HLH developing in 
autoinflammatory diseases, principally in systemic 
juvenile idiopathic arthritis. Interestingly, also various 
metabolic disorders, including lysinuric protein intol-
erance, multiple sulphatase deficiency and alterations 
of propionate metabolism are known to be potential 
triggers for HLH [8].
HLH is known to develop in patients with malig-
nancies, mainly lymphoproliferative disorders. Often, 
infections promote HLH in the context of a com-
promised immune system due to chemotherapy or 
cytokines produced by the tumor cells or infected 
T lymphocytes [9]. Among hematological malignan-
cies, lymphomas or leukemias of T or NK cell lines, 
which are frequently related to EBV infection, are the 
most frequently associated with HLH [5,10].
The association between hemophagocytosis and 
solid tumors is anecdotal and refers almost exclusively 
to HLH developed in patients with mediastinal germ 
cell tumors [11], pediatric neuroblastoma and rhab-
domyosarcoma, hepatocellular carcinoma [12], meta-
static melanoma [13], squamous cell carcinoma of the 
neck [14], lung cancer [15], renal cell carcinoma [16], 
prostate cancer [17] and colon cancer [18].
HLH is the result of uncontrolled hyperinflamma-
tory reaction to various types of triggers. The main 
physiopathological mechanism is an abnormal activa-
tion and proliferation of macrophages and CD8+ lym-
phocytes, and prominent cytokines production (includ-
ing IFN-γ, sIL-2R, IL-1, TNF-α, IL-6 and IL-18) 
induced by T-helper lymphocytes [19,20]. This hypercy-
tokinemia leads to an autoamplification loop of mac-
rophages and cytotoxic lymphocyte activation resulting 
in tissue damages. While the pathogenesis of primary 
HLH is largely understood, the mechanisms underly-
ing acquired HLH are not yet fully reco gnized [21,22].
In genetic HLH, hereditary mutations affect the 
transport, release and/or activity of cytolytic granules in 
NK cells and cytotoxic T lymphocytes (CTL). Cytotoxic 
granules contain perforin and granzymes that induce 
apoptosis of target cells. Moreover perforin is impor-
tant for the down-regulation of the immune response. 
As a result, despite NK and CTL granule-dependent 
cytotoxic activity is impaired, they can still activate and 
secrete cytokines, supporting a persistent activation of 
the immune response with tissue damage [22].
Different pathogenetic mechanisms can support 
acquired HLH. In most cases, there is not an impair-
ment of lymphocyte cytotoxic activity, although some 
heterozygous mutations in genes that regulate the 
innate immune response and the NK function have 
been correlated with secondary HLH [23]. In case of 
infections, mainly by intracellular microorganism, 
the pathogenesis lies in a direct activation of Toll-like 
receptors with disproportionate activation of normal 
macrophage and T cells, leading to a detrimental Th1 
cytotoxic response. The inability to deal with infec-
tions in immunocompromised patients can be a trig-
ger for HLH development: cells of the innate immune 
response are continuously activated via pattern recogni-
tion receptors (such as Toll-like receptors) that respond 
to components of opportunistic bacteria, mycoplasma, 
fungi, and viruses, sustaining an uncontrolled immune 
response. In autoimmune disorders, non-antigen-spe-
cific triggering of innate immunity may represent the 
precipitating factor [21]. Several cytokines released by 
malignancies may induce HLH [5]. HLC can be an 
extremely rare consequence of the cytotoxic effects of 
chemotherapy, whose massive tumor cell destruction 
results in a pathological immune response, leading to 
excessive cytokine production [14,17,24].
Given the poor prognosis, timely diagnosis is cru-
cial. There is no single feature that is pathognomonic 
for HLH, including hemophagocytosis. To facilitate 
the diagnosis, the HLH Study Group of the Histiocyte 
Society has established a panel of eight diagnostic crite-
ria, five of which are required for HLH. The utility of 
these criteria is questionable because they lack specific-
ity. Therefore, it is the coexistence of different clinical 
features (especially the triad of prolonged fever, hepato-
spleno- megaly- and cyto-penias) to become relevant [25].
Each clinical and laboratory finding is strictly related 
to the hyper-inflammation state of the disease. Macro-
phage and T-lymphocyte proliferation results in hepa-
tosplenomegaly and peripheral lymphadenopathy. Fever 
is secondary to high concentrations of IL-2 and IL-1. 
Cytopenias is ascribable to TNF-α and IFN-γ overpro-
duction that suppress hematopoiesis and direct hemo-
phagocytosis. Coagulopathy is often reported, and 
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due to macrophage secretion of plasminogen activators 
resulting in an accelerated conversion of plasminogen to 
plasmin and consequent hypofibrinogenemia. Dissemi-
nated intravascular coagulation can be a rare manifes-
tation of elevated levels of TNF-α and IFN-γ. Serum 
ferritin elevation induced by IL-1β is highly sensitive 
and specific for HLH. Hyper triglyceridemia is the con-
sequence of lipoprotein lipase inhibition by TNF-α.
As a severe condition, there should be no delay in 
starting therapy. The goal of treatment is to regulate the 
immune system dysfunction, suppressing the hyperin-
flammatory state. It is also important to treat the cause 
responsible for acquired HLH. Cortico steroids alone, or 
in association with intravenous immunoglobulin, repre-
sents the main therapy in patients with rheumatology-
associated HLH (macrophage activation syndrome), but 
may be also active for others secondary forms of HLH. 
In the latter case, however, the lack of a quick response 
should result in the promptly set up of full therapy, con-
sisting in immune-suppressive agents, cytotoxic drugs, 
biological response modifiers, and stem-cell transplan-
tation as suggested by the HLH-94 protocol. Unfortu-
nately, about 25% of patients fail to achieve complete 
remission with standard therapy. At the moment, there 
are no standard salvage therapies. No conclusive results 
are reported with the use of infliximab, daclizumab, 
alemtuzumab, anakinra and other agents [26].
Refractory patients generally have dismal prognosis, 
encouraging research aimed at a better understanding 
of disease pathogenesis so as to develop more effective 
therapies.
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